Home › Companies › ALDEYRA THERAPEUTICS INC. › 2024-2025

ALDEYRA THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and ALDEYRA THERAPEUTICS INC.’s Form 8-K, filed 2025-06-11 (Item 5.07 on EDGAR). Page generated 02 October 2026.

5Ballot items
131Asset managers
707Fund votes
2025-06-10Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ALDEYRA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ALDEYRA THERAPEUTICS INC.

These tallies are ALDEYRA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-11 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ALDEYRA THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-10
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Richard H. Douglas, Ph.D.	21,052,870	--	--	5,895,494	18,670,405	Majority: yes
Elect Director: Gary M. Phillips, M.D.	23,683,657	--	--	3,264,707	18,670,405	Majority: yes
Elect Director: Neal S. Walker, D.O.	23,791,102	--	--	3,157,262	18,670,405	Majority: yes
Proposal 2: Ratification of Appointment of BDO USA, P.C	44,860,758	653,760	104,251	--	--	Majority: yes
Proposal 3: Advisory Vote on Executive Compensation	18,847,620	7,919,279	181,465	--	18,670,405	Majority: yes

Source: ALDEYRA THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-11 — read the filing on EDGAR.

How asset managers voted at the ALDEYRA THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 131 asset managers that disclosed a ALDEYRA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on a non-binding, advisory basis, the compensation of Aldeyra Therapeutics, Inc.'s named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

70% Majority: yes · of votes cast

FOR 70%AGAINST 30%

FOR: 18,847,620AGAINST: 7,919,279

ALDEYRA THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation”): 18,847,620 for, 7,919,279 against, per its Form 8-K filed 2025-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,895,588 outstanding shares: 31% for, 13% against (45% of the company cast a for/against vote).

The 129 asset managers below cast 77% of the shares they voted on this item FOR (15,816,753 for, 4,750,634 against).

FOR 77%AGAINST 23%

FOR: 15,816,753 (76.9%)AGAINST: 4,750,634 (23.1%)NOT VOTED: 1,000 (0.0%)

Largest asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of Aldeyra Therapeutics, Inc.'s named executive” at ALDEYRA THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,819,926	0	For
PERCEPTIVE ADVISORS LLC	2,994,479	0	For
BlackRock	2,829,438	8,638	For
ARDSLEY ADVISORY PARTNERS LP	0	1,683,812	Against
KINGDON CAPITAL MANAGEMENT, L.L.C.	0	1,052,697	Against
GEODE CAPITAL MANAGEMENT, LLC	976,926	0	For
Fidelity	877,763	0	For
AQR	588,086	0	For
ADAR1 Capital Management, LLC	510,888	0	For
KENNEDY CAPITAL MANAGEMENT LLC	359,038	144,393	For
State Street	495,892	39	For
Invesco	0	413,083	Against
Dimensional	0	401,027	Against
Federated Hermes	0	384,401	Against
Charles Schwab	275,920	0	For
Northern Trust	264,370	0	For
Palo Alto Investors LP	225,465	0	For
WOODSTOCK CORP	0	223,094	Against
Equitable	150,144	0	For
PNC BANK, NATIONAL ASSOCIATION	0	144,784	Against
Nuveen	129,724	0	For
TIAA	128,345	0	For
Wellington	0	85,464	Against
QUANTITATIVE MASTER SERIES LLC	82,675	0	For
Lincoln Financial	68,346	10,494	For

Showing the 25 largest of 129 asset managers. See all 129 in the interactive database.

2. Election of three Class II Directors: Gary M. Phillips, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 23,683,657WITHHELD: 3,264,707

ALDEYRA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Gary M. Phillips, M.D.”): 23,683,657 for, 3,264,707 withheld, per its Form 8-K filed 2025-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,895,588 outstanding shares: 40% for, 5% withheld (45% of the company cast a for/withheld vote).

The 39 asset managers below cast 100% of the shares they voted on this item FOR (6,936,275 for, 0 against).

FOR 93%7%

FOR: 6,936,275 (92.6%)ABSTAIN: 551,402 (7.4%)

Largest asset managers voting on “Election of three Class II Directors: Gary M. Phillips, M.D.” at ALDEYRA THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,760,799	0	For
BlackRock	1,374,115	0	For
Fidelity	870,787	0	For
Dimensional	0	317,730	Abstain
Federated Hermes	0	191,902	Abstain
Equitable	150,144	0	For
Charles Schwab	137,946	0	For
TIAA	128,345	0	For
AQR	114,257	0	For
QUANTITATIVE MASTER SERIES LLC	82,675	0	For
Lincoln Financial	68,346	10,494	For
Global X	29,296	0	For
AIG/SunAmerica	25,448	0	For
Pacific Life	23,945	0	For
Northern Trust	21,827	0	For
Bridge Builder Trust	21,145	0	For
Jackson National	0	21,117	Abstain
John Hancock	18,394	0	For
Brighthouse	16,862	0	For
Nationwide	16,641	0	For
Voya	13,924	0	For
Prudential/PGIM	0	9,920	Abstain
ProShares	9,606	0	For
SEI	9,200	0	For
DWS	7,876	0	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

3. Election of three Class II Directors: Neal S. Walker, D.O.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 23,791,102WITHHELD: 3,157,262

ALDEYRA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Neal S. Walker, D.O.”): 23,791,102 for, 3,157,262 withheld, per its Form 8-K filed 2025-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,895,588 outstanding shares: 40% for, 5% withheld (45% of the company cast a for/withheld vote).

The 39 asset managers below cast 100% of the shares they voted on this item FOR (6,936,275 for, 0 against).

FOR 93%7%

FOR: 6,936,275 (92.6%)ABSTAIN: 551,402 (7.4%)

Largest asset managers voting on “Election of three Class II Directors: Neal S. Walker, D.O.” at ALDEYRA THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,760,799	0	For
BlackRock	1,374,115	0	For
Fidelity	870,787	0	For
Dimensional	0	317,730	Abstain
Federated Hermes	0	191,902	Abstain
Equitable	150,144	0	For
Charles Schwab	137,946	0	For
TIAA	128,345	0	For
AQR	114,257	0	For
QUANTITATIVE MASTER SERIES LLC	82,675	0	For
Lincoln Financial	68,346	10,494	For
Global X	29,296	0	For
AIG/SunAmerica	25,448	0	For
Pacific Life	23,945	0	For
Northern Trust	21,827	0	For
Bridge Builder Trust	21,145	0	For
Jackson National	0	21,117	Abstain
John Hancock	18,394	0	For
Brighthouse	16,862	0	For
Nationwide	16,641	0	For
Voya	13,924	0	For
Prudential/PGIM	0	9,920	Abstain
ProShares	9,606	0	For
SEI	9,200	0	For
DWS	7,876	0	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

4. Election of three Class II Directors: Richard H. Douglas, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD 22%

FOR: 21,052,870WITHHELD: 5,895,494

ALDEYRA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Richard H. Douglas, Ph.D.”): 21,052,870 for, 5,895,494 withheld, per its Form 8-K filed 2025-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,895,588 outstanding shares: 35% for, 10% withheld (45% of the company cast a for/withheld vote).

The 39 asset managers below cast 100% of the shares they voted on this item FOR (6,665,218 for, 0 against).

FOR 89%11%

FOR: 6,665,218 (89.0%)ABSTAIN: 822,459 (11.0%)

Largest asset managers voting on “Election of three Class II Directors: Richard H. Douglas, Ph.D.” at ALDEYRA THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,760,799	0	For
BlackRock	1,374,115	0	For
Fidelity	870,787	0	For
Dimensional	0	317,730	Abstain
Federated Hermes	0	191,902	Abstain
Equitable	91,494	58,650	For
Charles Schwab	137,946	0	For
TIAA	0	128,345	Abstain
AQR	114,257	0	For
QUANTITATIVE MASTER SERIES LLC	82,675	0	For
Lincoln Financial	32,346	46,494	Abstain
Global X	0	29,296	Abstain
AIG/SunAmerica	25,448	0	For
Pacific Life	23,945	0	For
Northern Trust	21,827	0	For
Bridge Builder Trust	21,145	0	For
Jackson National	0	21,117	Abstain
John Hancock	18,394	0	For
Brighthouse	16,862	0	For
Nationwide	16,641	0	For
Voya	13,924	0	For
Prudential/PGIM	0	9,920	Abstain
ProShares	9,606	0	For
SEI	0	9,200	Abstain
DWS	7,876	0	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

5. TO RATIFY THE APPOINTMENT OF BDO USA, P.C. AS ALDEYRA THERAPEUTICS, INC.'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

99% Majority: yes · of votes cast

FOR 99%

FOR: 44,860,758AGAINST: 653,760

ALDEYRA THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Ratification of Appointment of BDO USA, P.C”): 44,860,758 for, 653,760 against, per its Form 8-K filed 2025-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,895,588 outstanding shares: 75% for, 1% against (76% of the company cast a for/against vote).

The 39 asset managers below cast 100% of the shares they voted on this item FOR (7,487,677 for, 0 against).

FOR 100%

FOR: 7,487,677 (100.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF BDO USA, P.C. AS ALDEYRA THERAPEUTICS, INC.'S INDEPENDENT REGISTERED PUBLIC ACCOU” at ALDEYRA THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
Vanguard	3,760,799	For
BlackRock	1,374,115	For
Fidelity	870,787	For
Dimensional	317,730	For
Federated Hermes	191,902	For
Equitable	150,144	For
Charles Schwab	137,946	For
TIAA	128,345	For
AQR	114,257	For
QUANTITATIVE MASTER SERIES LLC	82,675	For
Lincoln Financial	78,840	For
Global X	29,296	For
AIG/SunAmerica	25,448	For
Pacific Life	23,945	For
Northern Trust	21,827	For
Bridge Builder Trust	21,145	For
Jackson National	21,117	For
John Hancock	18,394	For
Brighthouse	16,862	For
Nationwide	16,641	For
Voya	13,924	For
Prudential/PGIM	9,920	For
ProShares	9,606	For
SEI	9,200	For
DWS	7,876	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

Largest ALDEYRA THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of ALDEYRA THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 59,895,588 shares outstanding at the time of that meeting.

Top ALDEYRA THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	6.38%
2	PERCEPTIVE ADVISORS LLC	5.00%
3	BlackRock	4.74%
4	ARDSLEY ADVISORY PARTNERS LP	2.81%
5	KINGDON CAPITAL MANAGEMENT, L.L.C.	1.76%
6	GEODE CAPITAL MANAGEMENT, LLC	1.63%
7	Fidelity	1.47%
8	AQR	0.98%
9	ADAR1 Capital Management, LLC	0.85%
10	KENNEDY CAPITAL MANAGEMENT LLC	0.84%

Reported ALDEYRA THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ALDEYRA THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Perceptive Advisors LLC	8.14%	DEF14A
BlackRock	6.24%	13F
Vanguard Group	6.21%	13F
Todd C. Brady, M.D., Ph.D.	6.20%	DEF14A
Knoll Capital Management, LLC	6.00%	DEF14A
Stephen G. Machatha, Ph.D.	1.73%	DEF14A
State Street	1.71%	13F
Dimensional Fund Advisors	1.12%	13F
Morgan Stanley	0.93%	13F
Invesco	0.84%	13F

Percentages above are of 59,895,588 shares outstanding, as reported by ALDEYRA THERAPEUTICS INC. on its Form 10-Q dated 2025-05-12 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ALDEYRA THERAPEUTICS INC.’s 10-Q dated 2025-05-12. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At ALDEYRA THERAPEUTICS INC.'s shareholder meeting held 2025-06-10, in the 2024-2025 proxy season, 131 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 707 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of Aldeyra Therapeutics, Inc.'s… — FOR was 70% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ALDEYRA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-11.

ALDEYRA THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.